We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

HORIBA Medical

HORIBA ABX designs, develops and distributes worldwide, in vitro diagnostic systems for biological analysis in medica... read more Featured Products: More products

Download Mobile App





HORIBA Unveils New Compact Hematology Analyzers with Combined ESR and CBC/Diff

By LabMedica International staff writers
Posted on 31 Jul 2024

HORIBA (Kyoto, Japan) is attending this year's ADLM where the company is showcasing its newly launched compact hematology analyzers that offer combined testing for Erythrocyte Sedimentation Rate (ESR) and complete blood count (CBC)/differential (Diff). More...

HORIBA recently expanded its award-winning compact hematology instrument range with the launch of new models with ESR on board. At ADLM 2024, HORIBA is presenting the new Yumizen H550E (autoloader), H500E CT (closed tube), and Yumizen H500E OT (open tube) which now offer combined testing for CBC/DIFF with ESR results from whole blood in 60 seconds.

Visitors to HORIBA’s booth at ADLM 2024 can learn more about the company’s innovative CoRA (Correlated Rouleaux Analysis) technology that has been used to integrate ESR into its three new analyzers. Combining CBC and 5-population white blood cell differential with rapid ESR, calibrated to the Westergren reference method, on one compact analyzer reduces costs per test and turnaround times, and saves laboratory space. Both the Yumizen H550E and H500E models have been further enhanced by offering new connectivity possibilities for data management through HORIBA’s Yumizen P8000 middleware, along with Yumicare. This remote technical support tool enables secure connection to the instrument to monitor workload, reagent consumption, quality control, and instrument alarms.

Also featuring is the new Yumizen C230 benchtop chemistry analyzer for small-volume laboratories with advanced and user-friendly features. This compact integrated solution is designed with system simplicity for efficient performance and processes tests with disposable cuvettes, enabling efficient resource usage. Paired with high-quality POINTE reagents, the new Yumizen C230 provides reliable test results. In addition, HORIBA is showcasing the new Yumizen C240 chemistry analyzer which is designed with system simplicity for expedient and efficient performance. Ideal for mid-sized to small labs, the Yumizen C240 is a compact and cost-efficient analyzer offering full walk-away capabilities and advanced features such as a washing station and pre-warmed detergent water.

Related Links:
HORIBA


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Nasopharyngeal Applicator
CalgiSwab 5.5" Sterile Mini-tip Calcium Alginate Nasopharyngeal Swab w/Aluminum HDLE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.